The short version of immunomodulatory peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-05. Anything still debated is marked as such rather than presented as settled.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
On the same day the ICJ's ruling was made public, South African prime minister B. J. Vorster rejected it as "politically motivated", with no foundation in fact. However, the decision inspired the bishops of the Evangelical Lutheran Ovambo-Kavango Church to draw up an open letter to Vorster denouncing apartheid and South Africa's continued rule. This letter was read in every black Lutheran congregation in the territory, and in a number of Catholic and Anglican parishes elsewhere. The consequence of the letter's contents was increased militancy on the part of the black population, especially among the Ovambo people, who made up the bulk of SWAPO's supporters. Throughout the year there were mass demonstrations against the South African government held in many Ovamboland schools. In December 1971, Jannie de Wet, Commissioner for the Indigenous Peoples of South West Africa, sparked off a general strike by 15,000 Ovambo workers in Walvis Bay when he made a public statement defending the territory's controversial contract labour regulations. The strike quickly spread to municipal workers in Windhoek, and from there to the diamond, copper and tin mines, especially those at Tsumeb, Grootfontein, and Oranjemund. Later in the month, 25,000 Ovambo farm labourers joined what had become a nationwide strike affecting half the total workforce. The South African police responded by arresting some of the striking workers and forcibly deporting the others to Ovamboland.
== See also == First 100 days of the second Trump presidency – Period from January to April 2025 List of executive actions by Donald Trump Lists of presidential trips made by Donald Trump (international trips) Second presidential transition of Donald Trump – Transfer of presidential power from Joe Biden to Donald Trump Timeline of the 2024 United States presidential election
=== SELEX === Conventional (up to 1016 different oligonucleotides) existing molecule library serves as a starting point for the subsequent SELEX process. Selection, separation, and amplification using the mirror image of the target molecule is performed.
Sources: en.wikipedia.org
== Hfe knockout mice == It is possible to delete part or all of a gene of interest in mice (or other experimental animals), as a means of studying the function of the gene and its protein. Such mice are called "knockouts" with respect to the deleted gene. Hfe is the mouse equivalent of the human hemochromatosis gene HFE. The protein encoded by HFE is Hfe. Mice homozygous (two abnormal gene copies) for a targeted knockout of all six transcribed Hfe exons are designated Hfe−/−. Iron-related traits of Hfe−/− mice, including increased iron absorption and hepatic iron loading, are inherited in an autosomal recessive pattern. Thus, the Hfe−/− mouse model simulates important genetic and physiological abnormalities of HFE hemochromatosis. Other knockout mice were created to delete the second and third HFE exons (corresponding to α1 and α2 domains of Hfe). Mice homozygous for this deletion also had increased duodenal iron absorption, elevated plasma iron and transferrin saturation levels, and iron overload, mainly in hepatocytes. Mice have also been created that are homozygous for a missense mutation in Hfe (C282Y). These mice correspond to humans with hemochromatosis who are homozygous for HFE C282Y. These mice develop iron loading that is less severe than that of Hfe−/− mice.
== Type == The Prima Porta-type of statues of Augustus, of which Augustus of Prima Porta is the most famous example, became the prevailing representational style for him. This type was introduced around 27 BC to visually express the title Augustus and was copied full-length and in busts in various versions throughout the empire up until his death in AD 14. The copies never showed Augustus looking older, however, but represented him as forever young, in line with the aims of his propaganda, i.e. to display the authority of the Roman emperors through conventional styles and stories of the culture. At its best, in Roland R. R. Smith's view, this "type achieves a sort [of] visual paradox that might be described as mature, ageless, and authoritative youthfulness".
=== Pseudobulbar affect === Pseudobulbar affect (PBA) is a condition involving episodic uncontrollable laughter or crying. PBA mostly occurs in people with neurological injuries affecting how the brain controls emotions. Scientists believe PBA results from prefrontal cortex damage. PBA often involves crying. Hence, PBA is mistakable for depression. But PBA is neurological; depression is psychological. Patients with PBA do not experience typical depression symptoms like sleep disturbances or appetite loss.
Sources: en.wikipedia.org
== Applications == Bispecific antibodies have a wide variety of applications in diagnosis and therapy. BsAbs can be combined with HRPO, can be used in pre-targeting strategies, and can be used to provide better imaging for early detection in diagnosis. To treat cancer, BsAbs can target immune cells precisely, help and reactive the immune cells, fine-tune the fate and function of immune cells, improve the tolerance of immune cells, and promote the return to immune homeostasis. BsAbs can also be applied to treat other diseases, including hemophilia A, diabetes, Alzheimer's disease, and ophthalmological diseases.
=== Salts === Despite the reduction in relative permittivity, many salts remain soluble in superheated water until the critical point is approached. Sodium chloride, for example, dissolves at 37 wt% at 300 °C As the critical point is approached, solubility drops markedly to a few ppm, and salts are hardly soluble in supercritical water. Some salts show a reduction in solubility with temperature, but this behaviour is less common.
Two of his bodyguards and a female pedestrian were killed in the assassination attempt as well. While Tweeting from his hospital bed, Garcia blamed the CJNG for the failed attempt on his life and had 12 suspected CJNG members arrested by the end of the day. The same day, it emerged that the CJNG still controlled organized crime in Jalisco, Guanajuato, Querétaro, Hidalgo, but no longer was listed as having such control in any municipality in Veracruz and still was unable to take away territory in other parts of southeastern Mexico controlled by the Sinaloa Cartel, Los Zetas and the so-called Los Pelones group. Sánchez was later murdered, with his body being discovered stabbed and wrapped in plastic on a park bench in downtown Tlaquepaque on 18 March 2021. Emilio Alejandro Pulido Salazar would surrender to Mexican authorities the same month. Érick Valencia Salazar, alias "El 85", was presumed to be the head of the Nuevo Plaza Cartel at the time of El Cholo's death. In February 2022, leading CJNG operator in Michoacán and trusted El Mencho associate Miguel Ángel Fernández, known as "El M2", was found murdered in the town of Cansangüe, located in the municipality of Tepalcatepec El 85 was later captured by Mexican authorities in September 2022. By November 2021, El Mencho and his wife Rosalinda's younger sisters were the only CJNG members to remain at large who were also among the cartel's original founders. In May 2022, Insight Crime reporter Peter Appleby reported that El Mencho's poor health, and also rumored death, accelerated break-ups and infighting in the CJNG.
== Early life == Darshan Ranganathan was born as Darshan Markan on 4 June 1941 to Vidyavati Markan and Shanti Swarup in Delhi. She was educated in Delhi and received a Ph.D. in chemistry from Delhi University in 1967. First hired as a lecturer, she became head of the Chemistry Department at Miranda College, Delhi, and went on to receive an 1851 Research Fellowship from the Royal Commission for the Exhibition of 1851, to enable her to conduct postdoctoral work at Imperial College London with Professor D.H.R. Barton.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.